Joshua Farhadian, MD
MOHS-Micrographic Surgery · Great Neck, NYNPI 1184966012
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Incyte Corporation accounts for 65.0% of it on its own, with 2 other manufacturers making up the rest. That places this record below the midpoint for mohs-micrographic surgery clinicians in NY, where the typical reported total is $1,291.
Across 4 payments — averaging $96.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$250
- Lilly USA, LLC$118
- Cipher Pharmaceuticals US LLC$16
What the payments were for
- Food & beverage$385100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 2 | $250 |
| Lilly USA, LLC | 1 | $118 |
| Cipher Pharmaceuticals US LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPZELURA$250
How this compares
$385 in reported general payments places this provider in the 25th percentile of 75 mohs-micrographic surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mupirocin | 359 | $3,048 |
| Tacrolimus | 15 | $2,535 |
| Clobetasol Propionate | 70 | $2,516 |
| Clindamycin Phosphate | 53 | $2,159 |
| Ketoconazole | 104 | $1,871 |
| Triamcinolone Acetonide | 144 | $1,075 |
| Fluorouracil | 15 | $961 |
| Mometasone Furoate | 41 | $917 |
| ValacyclovirValacyclovir Hcl | 31 | $822 |
| Doxycycline Monohydrate | 51 | $607 |
| Metronidazole | 17 | $597 |
| Hydrocortisone | 116 | $557 |
| Ammonium Lactate | 13 | $359 |
| Cephalexin | 64 | $344 |
| Doxycycline Hyclate | 11 | $258 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Great Neck
- Daniel SiegelSmithtown$450K
- Sherrif IbrahimVictor$412K
- Kavita MariwallaWest Islip$221K
- Ellen MarmurNew York$186K
- Kenneth MarkSouthampton$91K
- Michael TassavorNew York$55K
- Jane YooNew York$42K
- Hamza BhattiNew York$40K
- Desiree RatnerNew York$32K
- Eyal LevitBrooklyn$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.